Illumina CFO Goswami to depart, former Summit Therapeutics exec Dhingra to succeed (updated)

Illumina

09/04/2024 22:28

(Adds details in paragraph 3, background in paragraphs 5-6)
       April 9 (Reuters) - Illumina  ILMN.O  said on Tuesday
Chief Financial Officer Joydeep Goswami will leave the gene
sequencing company and be succeeded by former Summit
Therapeutics'  SMMT.O  executive Ankur Dhingra.
    Goswami, who has more than two decades of experience in the
life sciences industry, was the CFO since early 2023 and will
serve as an adviser till June 30, the company said.
    Prior to Summit, Dhingra was the CFO at medical test maker
CareDx  CDNA.O . He has also spent about 18 years at equipment
maker Agilent Technologies  A.N .
    Illumina has also reaffirmed its forecast for the first
quarter and full-year 2024.
    The company had in February forecast its annual core
business revenue to be nearly flat as subdued demand for its
genetic testing tools and diagnostics products extends into this
year.
    Illumina had said in December it would divest cancer
diagnostic test maker Grail  GRAL.O  after the companies battled
both U.S. and European antitrust enforcers for more than two
years and faced fierce opposition from activist investor Carl
Icahn.
    

 (Reporting by Pritam Biswas in Bengaluru; Editing by Shilpi
Majumdar)
 ((Pritam.Biswas@thomsonreuters.com))